Bidirectional crosstalk between the epithelial-mesenchymal transition and immunotherapy: A bibliometric study

References

• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–17. doi:10.1038/nrclinonc.2016.66.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Dong H, Niu K, Zhang W, Feng K, Yang R, Zhang Y. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy. Apoptosis. 2023;28(9–10):1423–1435. doi:10.1007/s10495-023-01868-8.
   PubMed Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z.
   PubMed Web of Science ®Google Scholar
• Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11(6):1368–1397. doi:10.1158/2159-8290.CD-20-1209.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423-020-0488-6.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167–189. doi:10.1080/10408360902937809.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. doi:10.3322/caac.21596.
   PubMed Web of Science ®Google Scholar
• Fang P, Zhou J, Liang Z, Yang Y, Luan S, Xiao X, Li X, Zhang H, Shang Q, Zeng X, et al. Immunotherapy resistance in esophageal cancer: possible mechanisms and clinical implications. Front Immunol. 2022;13:975986. doi:10.3389/fimmu.2022.975986.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu J, Luo H, Meng X, Chen M, Zhu D. Wnt signaling pathway in cancer immunotherapy. Cancer Lett. 2022;525:84–96. doi:10.1016/j.canlet.2021.10.034.
   PubMed Web of Science ®Google Scholar
• Fan F, Liu P, Bao R, Chen J, Zhou M, Mo Z, Ma Y, Liu H, Zhou Y, Cai X, et al. A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy. Cancer Res. 2021;81(24):6233–6245. doi:10.1158/0008-5472.CAN-21-1547.
   PubMed Web of Science ®Google Scholar
• Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129. doi:10.1186/s13045-022-01347-8.
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15(3):195–206. doi:10.1016/j.ccr.2009.01.023.
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y. CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis. 2013;30(4):393–405. doi:10.1007/s10585-012-9545-6.
   PubMed Web of Science ®Google Scholar
• Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-Cadherin and N-Cadherin switch in Epithelial-to-Mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118. doi:10.3390/cells8101118.
   PubMed Web of Science ®Google Scholar
• Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15(1):18. doi:10.1186/s12943-016-0502-x.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629. doi:10.1038/nrclinonc.2017.44.
   PubMed Web of Science ®Google Scholar
• Debaugnies M, Rodriguez-Acebes S, Blondeau J, Parent MA, Zocco M, Song Y, de Maertelaer V, Moers V, Latil M, Dubois C, et al. RHOJ controls EMT-associated resistance to chemotherapy. Nature. 2023;616(7955):168–175. doi:10.1038/s41586-023-05838-7.
   PubMed Web of Science ®Google Scholar
• De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279–2297. doi:10.1007/s00204-021-03063-7.
   PubMed Web of Science ®Google Scholar
• Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Tumor immune microenvironment during Epithelial-Mesenchymal transition. Clin Cancer Res. 2021;27:4669–4679. doi:10.1158/1078-0432.CCR-20-4459.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–361. doi:10.1016/j.cell.2011.11.025.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81. doi:10.1016/j.canlet.2019.10.013.
   PubMed Web of Science ®Google Scholar
• Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer. 2015;14:149. doi:10.1186/s12943-015-0421-2.
   PubMed Web of Science ®Google Scholar
• Li S, Liu M, Do MH, Chou C, Stamatiades EG, Nixon BG, Shi W, Zhang X, Li P, Gao S, et al. Cancer immunotherapy via targeted TGF-beta signalling blockade in T(H) cells. Nature. 2020;587:121–125. doi:10.1038/s41586-020-2850-3.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang J, Huang G, Zhu J, Jian H, Xia G, Wei Q, Li Y, Yu H. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. Hepatol Int. 2022;16:906–917. doi:10.1007/s12072-022-10354-3.
   PubMed Web of Science ®Google Scholar
• Wu X, Ma S, Wu Z, Zhao Q. Global scientific trends on matrix metalloproteinase and osteosarcoma: a bibliometric and visualized analysis. Front Oncol. 2023;13:1064815. doi:10.3389/fonc.2023.1064815.
   PubMed Web of Science ®Google Scholar
• Wang S, Wu K, Zhang Z, Xu Z, Wu J, Xu S. Mapping theme trends and recognizing research hot spots in the use of ultrasound in orthopaedics: a bibliometric analysis of global research. Am J Transl Res. 2021;13:9892–9911.
   PubMed Web of Science ®Google Scholar
• Zhan J, Ma Y, Zhao D, Li Z, Tan H, Wang X, Liu H, Yang T. Knowledge atlas of post-traumatic epilepsy research: based on citespace visualization analysis. Epilepsy Res. 2021;178:106790. doi:10.1016/j.eplepsyres.2021.106790.
   PubMed Web of Science ®Google Scholar
• Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719–734. doi:10.1016/j.ccr.2014.04.005.
   PubMed Web of Science ®Google Scholar
• Heelan RT, Panicek DM, Burt ME, Caravelli JF, Martini N, Bains M, McCormack P, Koutcher JA, Cardini L. Magnetic resonance imaging of the postpneumonectomy chest: normal and abnormal findings. J Thorac Imaging. 1997;12(3):200–208. doi:10.1097/00005382-199707000-00006.
   PubMed Web of Science ®Google Scholar
• Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, Bin J, Liao Y, Rao J, Liao W. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737–750. doi:10.1158/2326-6066.CIR-18-0436.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166:21–45. doi:10.1016/j.cell.2016.06.028.
   PubMed Web of Science ®Google Scholar
• Perez-Riverol Y, Bai J, Bandla C, Garcia-Seisdedos D, Hewapathirana S, Kamatchinathan S, Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543–D552. doi:10.1093/nar/gkab1038.
   PubMed Web of Science ®Google Scholar
• Xu R, Yang Z, Fan J, Huang X, Long L, Yu S, Zhang X, Li X, Huang H. Knowledge base and emerging trends in YAP1 research. Am J Transl Res. 2022;14:6467–6483.
   PubMed Web of Science ®Google Scholar
• Lu C, Liu M, Shang W, Yuan Y, Li M, Deng X, Li H, Yang K. Knowledge mapping of angelica sinensis (Oliv.) Diels (Danggui) research: a scientometric study. Front Pharmacol. 2020;11:294. doi:10.3389/fphar.2020.00294.
   PubMed Web of Science ®Google Scholar
• Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14(1):14. doi:10.1186/s13045-020-01030-w.
   PubMed Web of Science ®Google Scholar
• Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647. doi:10.15252/embj.2021108647.
   PubMed Web of Science ®Google Scholar
• Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22(6):1499–1509. doi:10.1158/1078-0432.CCR-15-1125.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49.
   PubMed Web of Science ®Google Scholar
• Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76. doi:10.1186/s13045-019-0760-3.
   PubMed Web of Science ®Google Scholar
• Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361–374. doi:10.1016/j.devcel.2019.04.010.
   PubMed Web of Science ®Google Scholar
• Henke E, Nandigama R, Ergun S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2019;6:160. doi:10.3389/fmolb.2019.00160.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141–160. doi:10.20517/cdr.2019.10.
   PubMedGoogle Scholar
• Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;12(12):681–700. doi:10.1038/nrgastro.2015.173.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, et al. Tgfbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–548. doi:10.1038/nature25501.
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241. doi:10.1038/ncomms6241.
   PubMed Web of Science ®Google Scholar
• Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al. Epithelial-Mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016;22:3630–3642. doi:10.1158/1078-0432.CCR-15-1434.
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.027.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428. doi:10.1172/JCI39104.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–196. doi:10.1038/nrm3758.
   PubMed Web of Science ®Google Scholar
• Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Physician. 2021;104:171–178.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0.
   PubMed Web of Science ®Google Scholar
• Singh DD, Yadav DK. TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy. Biomedicines. 2021;9(8):876. doi:10.3390/biomedicines9080876.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188593. doi:10.1016/j.bbcan.2021.188593.
   PubMed Web of Science ®Google Scholar
• Zare M, Bastami M, Solali S, Alivand MR. Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol. 2018;233(5):3729–3744. doi:10.1002/jcp.26116.
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):253–260. doi:10.1007/s10911-010-9173-1.
   PubMed Web of Science ®Google Scholar
• Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11(7):824–846. doi:10.1002/1878-0261.12093.
   PubMed Web of Science ®Google Scholar
• Zhan HX, Zhou B, Cheng YG, Xu JW, Wang L, Zhang GY, Hu SY. Crosstalk between stromal cells and cancer cells in pancreatic cancer: new insights into stromal biology. Cancer Lett. 2017;392:83–93. doi:10.1016/j.canlet.2017.01.041.
   PubMed Web of Science ®Google Scholar
• Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. Epithelial-to-Mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982–3989. doi:10.1158/0008-5472.CAN-16-3292.
   PubMed Web of Science ®Google Scholar
• Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-beta and PD-L1. J Hematol Oncol. 2021;14:27. doi:10.1186/s13045-021-01045-x.
   PubMed Web of Science ®Google Scholar
• Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, et al. TGFbeta1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 2016;6:1366–1381. doi:10.1158/2159-8290.CD-15-1347.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369–380. doi:10.1016/j.ccr.2005.10.012.
   PubMed Web of Science ®Google Scholar
• Hao Y, Baker D, Ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. IJMS. 2019;20:2767. doi:10.3390/ijms20112767.
   Google Scholar
• Wik JA, Skalhegg BS. T cell metabolism in infection. Front Immunol. 2022;13:840610. doi:10.3389/fimmu.2022.840610.
   PubMedGoogle Scholar
• Chae YK, Chang S, Ko T, Anker J, Agte S, Iams W, Choi WM, Lee K, Cruz M. Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci Rep. 2018;8(1):2918. doi:10.1038/s41598-018-21061-1.
   PubMed Web of Science ®Google Scholar
• Xie F, Zhou X, Su P, Li H, Tu Y, Du J, Pan C, Wei X, Zheng M, Jin K, et al. Breast cancer cell-derived extracellular vesicles promote CD8(+) T cell exhaustion via TGF-beta type II receptor signaling. Nat Commun. 2022;13:4461. doi:10.1038/s41467-022-31250-2.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Q, Chen Y, Liang CL, Liu H, Qiu F, Dai Z. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother. 2020;121:109570. doi:10.1016/j.biopha.2019.109570.
   PubMed Web of Science ®Google Scholar
• Cai H, Ren Y, Chen S, Wang Y, Chu L. Ferroptosis and tumor immunotherapy: a promising combination therapy for tumors. Front Oncol. 2023;13:1119369. doi:10.3389/fonc.2023.1119369.
   PubMed Web of Science ®Google Scholar
• Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270–274. doi:10.1038/s41586-019-1170-y.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang J, Li S, Li L, Li L, Li D, Guo H, Gao D, Liu S, Ruan C, et al. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma. Front Immunol. 2022;13:1076045. doi:10.3389/fimmu.2022.1076045.
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Huergo-Zapico L, Galvan JA, Rodrigo L, de Herreros AG, Astudillo A, Gonzalez S. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol. 2013;190:4408–4419. doi:10.4049/jimmunol.1202950.
   PubMed Web of Science ®Google Scholar
• Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity. 2011;35:123–134. doi:10.1016/j.immuni.2011.04.019.
   PubMed Web of Science ®Google Scholar
• Xiao S, Liu X, Yuan L, Chen X, Wang F. Expression of ferroptosis-related genes shapes tumor microenvironment and pharmacological profile in gastric cancer. Front Cell Dev Biol. 2021;9:694003. doi:10.3389/fcell.2021.694003.
   PubMed Web of Science ®Google Scholar
• Mao Q, Min J, Zeng R, Liu H, Li H, Zhang C, Zheng A, Lin J, Liu X, Wu M. Self-assembled traditional Chinese nanomedicine modulating tumor immunosuppressive microenvironment for colorectal cancer immunotherapy. Theranostics. 2022;12(14):6088–6105. doi:10.7150/thno.72509.
   PubMed Web of Science ®Google Scholar